HK Stock Market Move | CHENMING PAPER (01812) fell over 3%, with expected loss to expand to at most 8.8 billion yuan by 2025.
Chenming Paper (01812) fell more than 3%, as of the time of publication, it fell by 3.53% to 0.82 Hong Kong dollars, with a turnover of 1.3429 million Hong Kong dollars.
CHENMING PAPER (01812) fell more than 3%, closing at a 3.53% drop at 0.82 Hong Kong dollars, with a turnover of 1.3429 million Hong Kong dollars.
On the news side, on the evening of January 30, CHENMING PAPER issued a profit warning. For the period from January 1, 2025 to December 31, 2025 (this reporting period), the company expects a net loss attributable to the shareholders of the listed company of 8.2 billion to 8.8 billion yuan, an increase from the net loss of about 7.411 billion yuan in the same period last year; the net loss after deducting non-recurring gains and losses is 7.55 billion to 8.15 billion yuan.
The announcement stated that the reason for the performance change is that the Huanggang base is producing normally in 2025, while the Shouguang, Jiangxi, and Jilin bases have basically stopped production in the first to third quarters, and the Zhanjiang base has stopped production for the whole year. During the period, the losses and maintenance costs due to the shutdown increased compared to the previous year, and the production and sales volume decreased significantly, affecting revenue and profit; at the same time, due to the shutdown, the company made impairment provisions for some assets, further affecting the current profit.
Related Articles

Sunflower Pharmaceutical Group (002737.SZ) has received acceptance for the registration application of the easy to live brand probiotic powder.

Zhejiang Gongdong Medical Technology (605369.SH) has obtained the Laboratory Accreditation Certificate from the China National Accreditation Service for Conformity Assessment (CNAS).

Bank of America Merrill Lynch: Maintains "buy" rating on HANG LUNG PPT (00101) with a target price of 10.4 Hong Kong dollars.
Sunflower Pharmaceutical Group (002737.SZ) has received acceptance for the registration application of the easy to live brand probiotic powder.

Zhejiang Gongdong Medical Technology (605369.SH) has obtained the Laboratory Accreditation Certificate from the China National Accreditation Service for Conformity Assessment (CNAS).

Bank of America Merrill Lynch: Maintains "buy" rating on HANG LUNG PPT (00101) with a target price of 10.4 Hong Kong dollars.

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


